<DOC>
	<DOC>NCT01370317</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple dose treatment with MK-1029 in adults with mild to moderate persistent asthma.</brief_summary>
	<brief_title>Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>If female, must be of nonchildbearing potential Have a history of mild to moderate asthma for at least 6 months Other than asthma, in general good health Able to perform reproducible pulmonary function testing Is a nonsmoker and/or has not used nicotine or nicotinecontaining products for at least 12 months Have body mass index (BMI) ≥17 kg/m^2, but ≤35 kg/m^2 Demonstrate a decrease in absolute forced expiratory volume in 1 second (FEV1) of &gt;20% from the Screening Visit to the Baseline Visit Experience a decrease in AM or PM peak expiratory flow (PEF) below the Stability Limit on any 2 consecutive days prior to the Baseline Visit Require the use of &gt;8 inhalations per day of shortacting beta2agonist metered dose inhaler (MDI) or &gt;2 nebulized treatments per day of 2.5 mg albuterol, on any 2 consecutive days from the Screening Visit up to the Baseline Visit Experience an exacerbation defined as a clinical deterioration of asthma, as judged by the clinical investigator, that results in emergency treatment, hospitalization due to asthma, or treatment with additional, excluded medication (other than shortacting beta agonists [SABA]) at any time from the Screening Visit up to the Baseline Visit Have been hospitalized for treatment of asthma or required oral corticosteroids for treatment of asthma within the past 6 months, or has ever required ventilator support for respiratory failure secondary to asthma Require the chronic use of highdose inhaled corticosteroids Have been diagnosed with chronic obstructive pulmonary disease (COPD) or any other clinically relevant lung disease, other than asthma Have a history of any illness that might confound the results of the study or poses additional risk to the participant Have had recent (within 4 weeks of first dose) or ongoing upper or lower respiratory tract infection Is nursing Have a history of significant multiple and/or severe allergies (including latex allergy), or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>